ARS Pharms SEC Filings

Form 4 highlights: On 06/25/2025 ARS Pharmaceuticals, Inc. (SPRY) granted Director Pratik Shah a stock option for 30,000 common shares at an exercise price of $17.26 per share. The option vests in full on the earlier of 25 June 2026 or the date of the company’s 2026 annual shareholder meeting, and expires on 24 June 2035. Following this grant, Mr. Shah beneficially owns 30,000 derivative securities; all are held directly. No non-derivative share transactions were reported.

The filing reflects a routine equity incentive award to a non-employee director and does not indicate any open-market buying or selling. As such, it provides limited insight into current insider sentiment but does add a small potential dilutive element (≈30 k shares) to SPRY’s future share count if and when the option is exercised.

ARS Pharmaceuticals, Inc. (SPRY) – Form 4 insider filing dated 06/27/2025

Director Michael Kelly was granted a non-qualified stock option for 30,000 common shares on 06/25/2025 at an exercise price of $17.26 per share. The option vests in full on the earlier of June 25, 2026 or the date of the company’s 2026 annual meeting of stockholders, and carries a ten-year term expiring on 06/24/2035.

The filing reports no open-market purchases or sales of common stock; all activity relates to derivative securities. Following the grant, Mr. Kelly’s beneficial ownership comprises 30,000 derivative securities held directly. No indirect holdings or other related-party transactions were disclosed.

This one-year vesting schedule is consistent with typical board compensation practices and is intended to align the director’s incentives with shareholder interests. Because the award represents routine director compensation and does not involve cash expenditures or immediate dilution, it is unlikely to have a material impact on near-term financial performance or share count.

Form 4 filing overview – ARS Pharmaceuticals, Inc. (SPRY)

On 25 June 2025, director Saqib Islam received a new grant of derivative securities in the form of stock options. The filing reports one transaction and shows no changes to any non-derivative share holdings.

• Security granted: Stock option (right to buy)
• Amount: 30,000 options
• Exercise price: $17.26 per share
• Date exercisable: Grant vests in full on the earlier of 25 June 2026 or the company’s 2026 annual meeting.
• Expiration: 24 June 2035 (10-year term)
• Ownership after transaction: 30,000 derivative securities held directly by the reporting person.

The transaction is coded "A" (acquired), indicating an option grant rather than an open-market purchase or sale. No price was paid for the option itself; the $17.26 will be payable only upon future exercise. The filing shows Mr. Islam continues to serve as a director of ARS Pharmaceuticals and submitted the form individually. No other insiders or joint filers are listed.

Investors should note that the grant aligns the director’s potential future ownership with shareholder value creation, but it does not immediately affect the company’s outstanding share count or cash position.

ARS Pharmaceuticals, Inc. (SPRY) filed a Form 4 on 06/27/2025 disclosing an equity award to director Peter A. Thompson. The transaction, dated 06/25/2025, involves the grant of 30,000 non-qualified stock options with an exercise price of $17.26 per share, corresponding to the company’s common stock.

The options vest in full on the earlier of June 25 2026 or the date of SPRY’s 2026 annual shareholder meeting, and they carry a 10-year term expiring on June 24 2035. Following the grant, Thompson’s beneficial ownership consists solely of these 30,000 derivative securities, reported as direct (D) ownership.

Per a standing agreement, all economic benefits from the award will be transferred to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which in turn will pass them to OrbiMed Private Investments VI, LP. No open-market purchase or sale of common shares was reported, and no changes were disclosed for non-derivative holdings.

This filing represents a routine director compensation grant that modestly increases SPRY’s potential share count but primarily serves to align long-term incentives with shareholder value.

Form 4 Overview: On 06/25/2025, ARS Pharmaceuticals, Inc. (ticker: SPRY) filed a Form 4 detailing an insider transaction by Director Brent L. Saunders.

Key Details:

• Security Granted: Stock Option (right to buy common stock)
• Quantity: 30,000 options
• Exercise Price: $17.26 per share
• Grant Date: 06/25/2025
• Expiration: 06/24/2035
• Vesting: 100% on the earlier of 25 June 2026 or the date of the company’s 2026 annual shareholder meeting (exact meeting date not yet set).
• Ownership Form: Direct (D)

No common shares were bought or sold in Table I; the filing solely reports an acquisition of derivative securities in Table II. Following the grant, Saunders beneficially owns 30,000 derivative securities (options) with no indirect holdings disclosed.

Implications for Investors: The option award is a routine director compensation action that aligns leadership incentives with shareholder value. It does not involve an open-market purchase or sale of equity and therefore has limited immediate impact on the company’s share float or insider sentiment.

ARS Pharmaceuticals, Inc. (SPRY) – Form 4 insider filing dated 06/27/2025

The filing reports a single equity incentive transaction for director Phillip M. Schneider. On 06/25/2025 Mr. Schneider received 30,000 non-qualified stock options with an exercise price of $17.26 per share, equal to the closing market price on the grant date (implied from standard practice; no discount indicated). The award vests in full on the earlier of June 25 2026 or the date of the company’s 2026 annual shareholders meeting, and will expire on 06/24/2035 if unexercised. No shares were sold or purchased in the open market, and there were no changes to Mr. Schneider’s previously held common shares.

Following the grant, Mr. Schneider beneficially owns 30,000 derivative securities (options) directly. The filing contains no additional derivative or non-derivative transactions, amendments, or 10b5-1 plan indications.

The transaction is typical annual director compensation and does not alter the company’s share count immediately; any potential dilution is deferred until exercise. Investors typically view such grants as routine governance practice that aligns board incentives with shareholder value but has minimal near-term financial impact.

ARS Pharmaceuticals (Nasdaq: SPRY) filed an 8-K disclosing the voting results of its 2025 Annual Meeting held on June 25, 2025.

• All four Class II director nominees—Richard Lowenthal, Peter Kolchinsky, Brenton Saunders and Peter Thompson—were elected to serve until the 2028 meeting.
• Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2025 with 77,258,380 votes for (≈99.5%).

No other proposals were considered and the disclosure contains no material changes to strategy, operations or financial outlook.

3D Systems Corporation (NYSE: DDD) filed an 8-K detailing the completion of a $92.0 million private placement of 5.875% Convertible Senior Secured Notes due 2030. The notes were issued on 23 June 2025 under an indenture with Wilmington Savings Fund Society, FSB acting as trustee and collateral agent. Net proceeds after expenses were approximately $87.9 million.

Key terms: the notes pay 5.875% interest, semi-annually on 15 June and 15 December, commencing 15 December 2025, and mature 15 June 2030. Holders may convert at any time until two trading days before maturity at an initial rate of 445.6328 shares per $1,000 principal (conversion price ≈ $2.24), a 20% premium to the 17 June 2025 closing price of $1.87. The company may settle conversions in cash, stock, or a combination.

The notes carry several investor protections. Holders have a one-time put right on 20 June 2028 to require repurchase at par plus accrued interest. They may also demand repurchase upon a “fundamental change,” and receive an increased conversion rate in certain change-of-control or early-redemption scenarios. The company can redeem the notes, in whole or part, on or after 20 June 2028 if the share price equals at least 130% of the conversion price for a specified period.

Security & covenants: the obligations are senior secured and guaranteed by designated subsidiaries, with first-priority liens on substantially all assets except certain intellectual property. A breach of the limitation-on-liens covenant relating to IP would automatically extend the security interest to all IP assets. The indenture imposes additional restrictions on incurring indebtedness, liens, investments, and restricted payments.

Use of proceeds: (i) approximately $87.9 million of net proceeds plus ≈ $77.9 million cash on hand were used to repurchase a portion of the company’s outstanding 0% Convertible Senior Notes due 2026; (ii) ≈ $15.0 million cash on hand was used to repurchase common stock. The notes were sold in reliance on the Section 4(a)(2) private-placement exemption; shares issuable upon conversion are unregistered and may only be resold pursuant to an applicable exemption.

A press release announcing pricing was issued on 18 June 2025 (Exhibit 99.1). Exhibits 4.1 and 4.2 contain the full indenture and note form. No earnings figures or revised guidance were provided.